Metabolism of homocysteine and its relationship with cardiovascular disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical mechanisms and clinical hypotheses without systematic review methodology or new data.
PubMed 15789174 · doi:10.1007/s11239-004-0204-x
What was done
This is a narrative review examining the biochemical pathways of homocysteine metabolism (remethylation via MTHFR and transsulfuration via CBS), the genetic and nutritional causes of elevated plasma homocysteine (>15 µg/dL), the proposed mechanisms of cardiovascular injury, and ongoing trials evaluating homocysteine-lowering therapy using folic acid.
What was found
The abstract reports that hyperhomocysteinemia occurs when remethylation or transsulfuration pathways are inhibited or saturated, commonly driven by mutations in MTHFR and CBS, nutritional deficiencies, and demographic factors. Proposed vascular mechanisms include direct endothelial damage, oxidative stress generation, and induction of a procoagulant and proinflammatory state. The abstract provides no quantitative clinical outcome data or trial effect sizes.
Why it matters
The paper outlines the metabolic and mechanistic rationale linking elevated homocysteine to cardiovascular disease and highlights the need for prospective randomized trials to verify if lowering homocysteine with folate translates to clinical risk reduction.
Limits
This is a narrative overview without a systematic search strategy, formal study selection criteria, or meta-analytic data synthesis. No quantitative clinical efficacy or safety metrics are presented in the abstract.
Cited by
- contradicts Homocysteine is normally metabolized through the urea cycle to succinate by the enzyme methylenetetrahydrofolate reductase (MTHFR).